Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Shi S.
In der Rubrik Zeitschriften haben wir 2 Beiträge für Sie gefunden
-
From API to Nano Drug Product
Rubrik: Originale
(Treffer aus pharmind, Nr. 07, Seite 546 (2026))
Shi S | Schmidt A | Eugster D | Grave A
From API to Nano Drug Product / Part 2: Preparation and Characterization of Nanosuspensions, Loaded Granules, and Pellets*Part 1 see Pharm. Ind. 2026;88(6):470–474. · Shi S, Schmidt A, Eugster D, Grave A · Glatt Pharmaceutical Services und Willy A. Bachofen und Glatt Pharmaceutical Services
Particle Size Morphology Redispersibility Dissolution Stability To establish a stable nanomilling process, 2.5 % Kollidon® VA 64 was selected as a stabilizer together with 0.25 % SDS in the naproxen (nano)suspensions [ 13 , 16 ]. This combination played an important role in the successful nanomilling of naproxen nanoparticles as well as in maintaining nanosuspension stability during storage prior to fluid bed processing (approx. 3 d). For the determination of basic process parameters, initial experiments were conducted on a small-scale wet bead mill with a batch size of 2 kg. The parameters were then scaled up to a manufacturing-scale wet bead mill with an 8 kg batch ...
-
From API to Nano Drug Product
Rubrik: Originale
(Treffer aus pharmind, Nr. 06, Seite 470 (2026))
Shi S | Schmidt A | Eugster D | Grave A
From API to Nano Drug Product / Part 1: Manufacturing Process, Materials, and Methods · Shi S, Schmidt A, Eugster D, Grave A · Glatt Pharmaceutical Services und Willy A. Bachofen und Glatt Pharmaceutical Services
Wet Bead Milling Fluid Bed Top-Spray Granulation Drug Layering Pellets Active pharmaceutical ingredients (APIs) with poor aqueous solubility, especially when associated with limited dissolution rates, pose a significant challenge in pharmaceutical development, as they limit bioavailability and therapeutic efficacy [ 1 ]. This issue has become more critical, affecting up to 70 % to 90 % of certain newly identified APIs [ 2 ]. These APIs, due to their low solubility, are typically categorized as Biopharmaceutical Classification System (BCS) Class II or Class IV [ 3 ]. The solubility issue is particularly pertinent for oral administration, which remains the most prevalent and desired route for drug delivery. ...
